Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2019-06-17

FDA Approved: SPINRAZA — Supplemental Application (Biogen Inc.)

View source ↗

Summary

FDA approved Biogen's supplemental application for Spinraza (nusinersen). Spinraza is used to treat spinal muscular atrophy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Spinraza (nusinersen)

Snippet

SUPPL AP for SPINRAZA (NUSINERSEN)